首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 基因療法

市場調查報告書

商品編碼

2023933

基因治療市場預測—全球分析（治療方法、載體類型、遞送方法、給藥途徑、治療領域、基因類型、研發階段、應用、最終用戶和地區分類）—2034年

Gene Therapy Market Forecasts to 2034 - Global Analysis By Therapy Type, Vector Type, Delivery Method, Route of Administration, Therapeutic Area, Gene Type, Stage of Development, Application, End User, and By Geography

出版日期: 2026年04月17日 | 出版商:

Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

全球基因療法市場預計到 2026 年將達到 124 億美元，並在預測期內以 21.1% 的複合年成長率成長，到 2034 年達到 576 億美元。

基因療法是治療方法。這種突破性的醫療手段為過去難以治療的疾病，例如遺傳性疾病、某些癌症和罕見遺傳疾病，提供了潛在的治療方法。目前，基因療法市場涵蓋多種遞送機制、給藥途徑和載體技術，並且正在進行的研究正在拓展其在腫瘤學、神經病學、眼科學和血液學等領域的治療應用，從根本上改變了慢性病和危及生命的疾病的治療方式。

遺傳性疾病和罕見病患疾病率增加

血友病、肌肉萎縮症、囊性囊腫纖維化和鐮狀貧血等遺傳性疾病的日益普遍，使得人們迫切需要治療方法。傳統治療方法通常只能控制症狀，而無法解決根治性的遺傳病因，迫使患者終身服藥，嚴重影響其生活品質。基因療法有望透過一次性治療來糾正或取代缺陷基因，從而顯著減輕患者終身的醫療負擔。新生兒篩檢計畫的擴展和先進基因檢測技術的進步，正在識別出更多可能適合基因療法的患者，擴大目標患者群體，並刺激對多種疾病治療方法方案研發的持續投入。

高昂的醫療費用和報銷難題。

目前，每位患者的治療費用高達數十萬美元至超過200萬美元，這些具有治癒潛力的治療方法面臨著巨大的准入障礙。高昂的費用反映了複雜的生產流程、特殊的劑量要求和大量的研發投入，同時也為全球的醫療預算和保險體系帶來了沉重負擔。製造商和支付方之間的報銷談判常常會延誤患者的治療，而包括年金和績效合約在內的其他支付模式仍處於試驗階段，且普及率參差不齊。由於缺乏真實世界持久性數據，衛生技術評估機構難以評估治療方法的長期提案，這種不確定性減緩了市場擴張，並限制了已開發經濟體和新興經濟體患者的治療機會。

擴大病毒載體生產能力

對生產基礎設施的大量投資正在緩解傳統供應瓶頸，這些瓶頸曾經限制了臨床開發和商業化應用。合約開發和生產組織（CDMO）正在建造專門用於生產腺結合病毒和慢病毒載體的設施，採用創新的懸浮培養和純化技術來提高產量並降低成本。產能的擴張將使中小型生技公司能夠推進其在研候選藥物的研發，而無需對生產能力進行大規模的資本投資。生產效率的提高有望從長遠來看降低治療成本，並將目標患者群體從極其罕見的疾病擴展到基因療法先前在經濟上不可行的情況下更為常見的疾病。

長期安全性的不確定性和免疫反應

關於延遲不利事件（包括可能導致惡性腫瘤的插入突變）的未決問題持續抑制著監管機構的熱情和投資者的信心。病毒載體和基因改造產品的免疫反應可能抵消治療效果、誘發發炎反應，或限制已獲得部分緩解患者的再次用藥選擇。相當一部分一般人群對常用病毒載體存在既往免疫，這限制了某些治療方法的合格。已通過核准療法的追蹤期相對較短，這意味著其長期安全性數據尚不完整，導致監管機構採取謹慎態度。這造成了審查週期延長、上市後監測要求嚴格、研發成本增加以及市場不確定性加劇。

新冠疫情的影響：

新冠疫情擾亂了基因療法的臨床試驗和生產運營，但也展現了基因藥物平台的巨大潛力。由於醫療系統優先應對疫情，暫停了非緊急手術並限制了患者前往研究機構，臨床試驗的招募工作被大幅推遲。然而，mRNA疫苗的顯著成功加深了監管機構對基因藥物方法的理解，並簡化了基因療法的核准流程。供應鏈中斷凸顯了即時生產模式的脆弱性，促使企業採取策略性儲備和分散生產能力的策略。疫情的長期影響包括：遠距臨床試驗監測的監管柔軟性增強，以及突破性基因治療方法的核准時間縮短。

在預測期內，體內基因治療領域預計將佔據最大的市場規模。

預計在預測期內，體內基因治療領域將佔據最大的市場佔有率，這主要得益於其更簡便的給藥流程以及在多種適應症中不斷取得的臨床成功。此方法利用病毒或非病毒載體將治療性遺傳物質直接遞送至患者體內，無需細胞萃取、體外修飾和再次注射。簡化的物流流程降低了生產複雜性和治療成本，並且通常可以實現門診給藥。近期，脊髓性肌肉萎縮症和遺傳性視網膜疾病的體內療法獲得監管部門核准，凸顯了該方法的有效性，並推動了對血友病、Duchenne氏肌肉失養症和神經退化性疾病等在研藥物的大量投資。

在預測期內，鞘內給藥領域預計將呈現最高的複合年成長率。

在預測期內，鞘內給藥領域預計將呈現最高的成長率，這反映出人們對中樞神經系統疾病基因療法日益成長的興趣。這種給藥途徑繞過了血腦障壁傳統上限制了藥物向神經靶點的遞送），將治療藥物直接輸送到脊髓周圍的腦脊髓液中。與全身給藥相比，鞘內給藥可以降低載體劑量，同時提高目標神經組織內的藥物濃度，並減少脫靶效應和免疫暴露。這種方法對於脊髓性肌肉萎縮症、肌肉萎縮側索硬化症和影響中樞神經系統的溶小體儲積症尤其具有前景，並在多項後期臨床試驗中展現出顯著的療效和可接受的安全性。

市佔率最大的地區：

在整個預測期內，北美預計將佔據最大的市場佔有率，這得益於其集中的生物技術專長、有利的監管環境和充足的研發資金。美國在基因療法的臨床試驗和核准產品方面處於世界領先地位，食品藥物管理局的快速核准程序使患者能夠迅速獲得突破性治療方法。強大的智慧財產權保護吸引了創業投資投資，為從學術發現到商業性化應用的整個研發管線提供資金支持。完善的報銷體系，包括針對罕見疾病的專項醫療補助計劃和涵蓋昂貴專科治療的私人保險，確保患者即使面臨高昂的費用也能獲得治療。這個由創新、投資和病患可近性所構成的綜合生態系統，將成為北美在整個預測期內保持市場領先地位的驅動力。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於政府對基因組醫學的投資、大規模的遺傳疾病患者群體以及醫療基礎設施的改善。中國正崛起為基因治療領域的強勁競爭者，監管改革加速了臨床試驗的核准和產能的擴張。日本的再生醫學產品報銷系統為獲得監管部門核准後的商業性成功提供了可預測的路徑。印度快速發展的生物技術產業正在開發低成本的生產方法，這有望顯著擴大新興市場獲得治療的機會。除了大規模人口中遺傳疾病盛行率的不斷上升外，醫療保健支出的成長以及臨床研究領域的國際合作也是推動亞太地區在預測期內實現最快市場擴張的因素。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

企業概況
- 對其他市場參與者（最多 3 家公司）進行全面分析
- 對主要企業進行SWOT分析（最多3家公司）
區域細分
- 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
競爭性標竿分析
- 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 荷蘭
- 比利時
- 瑞典
- 瑞士
- 波蘭
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 澳洲
- 印尼
- 泰國
- 馬來西亞
- 新加坡
- 越南
- 其他亞太國家
南美洲
- 巴西
- 阿根廷
- 哥倫比亞
- 智利
- 秘魯
- 其他南美國家
世界其他地區（RoW）
- 中東
  - 沙烏地阿拉伯
  - 阿拉伯聯合大公國
  - 卡達
  - 以色列
  - 其他中東國家
- 非洲
  - 南非
  - 埃及
  - 摩洛哥
  - 其他非洲國家

第15章策略市場資訊

工業價值網路和供應鏈評估
空白區域和機會地圖
產品演進與市場生命週期分析
通路、經銷商和打入市場策略的評估

第16章產業趨勢與策略舉措

併購
夥伴關係、聯盟和合資企業
新產品發布和認證
擴大生產能力和投資
其他策略舉措

第17章：公司簡介

Novartis AG
Roche Holding AG
Pfizer Inc.
Johnson & Johnson
Gilead Sciences Inc.
Bluebird Bio Inc.
BioMarin Pharmaceutical Inc.
Spark Therapeutics Inc.
Sarepta Therapeutics Inc.
UniQure NV
CRISPR Therapeutics AG
Editas Medicine Inc.
Intellia Therapeutics Inc.
Orchard Therapeutics plc
Voyager Therapeutics Inc.
REGENXBIO Inc.
Abeona Therapeutics Inc.
Krystal Biotech Inc.

簡介目錄圖表

Product Code: SMRC35145

According to Stratistics MRC, the Global Gene Therapy Market is accounted for $12.4 billion in 2026 and is expected to reach $57.6 billion by 2034 growing at a CAGR of 21.1% during the forecast period. Gene therapy involves the introduction, removal, or modification of genetic material within a patient's cells to treat or prevent disease by addressing underlying genetic abnormalities. This revolutionary approach to medicine offers potential cures for previously untreatable conditions including inherited disorders, certain cancers, and rare genetic diseases. The market encompasses various delivery mechanisms, administration routes, and vector technologies, with ongoing research expanding therapeutic applications across oncology, neurology, ophthalmology, and hematology, fundamentally transforming the treatment landscape for chronic and life-threatening conditions.

Market Dynamics:

Driver:

Rising prevalence of genetic disorders and rare diseases

Increasing incidence of inherited conditions, including hemophilia, muscular dystrophy, cystic fibrosis, and sickle cell anemia, is creating urgent demand for curative rather than symptomatic treatments. Traditional therapies often manage symptoms without addressing root genetic causes, leaving patients with lifelong medication regimens and compromised quality of life. Gene therapy offers the potential for one-time treatments that correct or compensate for defective genes, dramatically reducing healthcare burdens over patient lifetimes. Growing newborn screening programs and advanced genetic testing capabilities are identifying more patients eligible for gene-based interventions, expanding addressable populations and driving continued investment in therapeutic development across multiple disease categories.

Restraint:

Exorbitant treatment costs and reimbursement challenges

Therapies currently priced between several hundred thousand and over two million dollars per patient create significant accessibility barriers despite their curative potential. These high costs reflect complex manufacturing processes, specialized delivery requirements, and extensive research investments, but strain healthcare budgets and insurance systems globally. Reimbursement negotiations between manufacturers and payers often delay patient access while alternative payment models, including annuity-based and outcomes-based agreements, remain experimental and inconsistently adopted. Health technology assessment bodies struggle to evaluate long-term value propositions for therapies with limited real-world durability data, creating uncertainty that slows market expansion and limits patient access across both developed and emerging economies.

Opportunity:

Expansion of viral vector manufacturing capacity

Significant investments in manufacturing infrastructure are addressing historical supply constraints that limited clinical development and commercial rollout. Contract development and manufacturing organizations are building dedicated facilities for adeno-associated virus and lentiviral vector production, employing innovative suspension cell cultures and purification technologies to increase yields while reducing costs. These capacity expansions enable smaller biotechnology companies to advance pipeline candidates without prohibitive capital investments in manufacturing capabilities. Improved production efficiency translates to lower therapy costs over time, potentially expanding addressable patient populations beyond ultra-rare indications into more common diseases where gene therapy approaches were previously economically unviable.

Threat:

Long-term safety uncertainties and immune responses

Unresolved questions about delayed adverse events, including potential insertional mutagenesis leading to malignancies, continue to temper regulatory enthusiasm and investor confidence. Immune reactions against viral vectors or transgene products can neutralize therapeutic effects, trigger inflammatory responses, or limit redosing options for patients with partial responses. Pre-existing immunity to commonly used viral vectors in substantial portions of the general population restricts patient eligibility for certain therapeutic approaches. The relatively short follow-up duration for approved therapies means long-term safety profiles remain incompletely characterized, creating regulatory caution that extends review timelines and imposes rigorous post-marketing monitoring requirements that increase development costs and market uncertainty.

Covid-19 Impact:

The COVID-19 pandemic disrupted gene therapy clinical trials and manufacturing operations while simultaneously validating the potential of genetic medicine platforms. Clinical trial enrollment faced significant delays as healthcare systems prioritized pandemic response, suspending non-essential procedures and limiting patient access to research sites. However, the remarkable success of mRNA vaccines accelerated regulatory comfort with genetic medicine approaches, streamlining pathways for gene therapy approvals. Supply chain disruptions highlighted vulnerabilities in just-in-time manufacturing models, prompting strategic stockpiling and geographic diversification of production capabilities. The pandemic's lasting impact includes increased regulatory flexibility for remote trial monitoring and accelerated review timelines for breakthrough genetic therapies.

The In Vivo Gene Therapy segment is expected to be the largest during the forecast period

The In Vivo Gene Therapy segment is expected to account for the largest market share during the forecast period, driven by its more straightforward administration process and growing clinical success across multiple indications. This approach delivers therapeutic genetic material directly into a patient's body using viral or non-viral vectors, eliminating the need for cell extraction, ex vivo modification, and reinfusion procedures. The simplified logistics reduce manufacturing complexity and treatment costs while enabling outpatient administration in many cases. Recent regulatory approvals for in vivo therapies targeting spinal muscular atrophy and inherited retinal diseases have validated this approach, encouraging substantial investment in pipeline candidates for hemophilia, Duchenne muscular dystrophy, and neurodegenerative disorders.

The Intrathecal segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Intrathecal segment is predicted to witness the highest growth rate, reflecting increasing research focus on gene therapies for central nervous system disorders. This route of administration delivers therapeutic agents directly into the cerebrospinal fluid surrounding the spinal cord, bypassing the blood-brain barrier that traditionally limits drug delivery to neurological targets. Intrathecal delivery enables lower vector doses compared to systemic administration while achieving higher concentrations in target neural tissues, reducing off-target effects and immune exposure. The approach shows particular promise for spinal muscular atrophy, amyotrophic lateral sclerosis, and lysosomal storage disorders affecting the central nervous system, with multiple late-stage clinical trials demonstrating meaningful efficacy and acceptable safety profiles.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by concentrated biotechnology expertise, favorable regulatory pathways, and substantial research funding. The United States leads globally in gene therapy clinical trials and approved products, with the Food and Drug Administration's accelerated approval mechanisms enabling rapid patient access to breakthrough treatments. Strong intellectual property protections attract venture capital investment, funding pipeline development from academic discoveries through commercial validation. Established reimbursement infrastructure, including specialized Medicaid programs for rare diseases and private insurance coverage for high-cost specialty therapies, enables patient access despite premium pricing. This comprehensive ecosystem of innovation, investment, and patient access sustains North American market leadership throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by government investments in genomic medicine, large patient populations with genetic disorders, and improving healthcare infrastructure. China has emerged as a significant gene therapy competitor, with regulatory reforms accelerating clinical trial approvals and manufacturing capacity expansion. Japan's reimbursement system for regenerative medicine products provides a predictable pathway for commercial success following regulatory authorization. India's growing biotechnology sector is developing lower-cost manufacturing approaches that could dramatically expand treatment accessibility across emerging markets. Increasing prevalence of genetic disorders in large populations, combined with rising healthcare expenditure and international collaboration in clinical research, positions Asia Pacific for the most rapid market expansion over the forecast period.

Key players in the market

Some of the key players in Gene Therapy Market include Novartis AG, Roche Holding AG, Pfizer Inc., Johnson & Johnson, Gilead Sciences Inc., Bluebird Bio Inc., BioMarin Pharmaceutical Inc., Spark Therapeutics Inc., Sarepta Therapeutics Inc., UniQure NV, CRISPR Therapeutics AG, Editas Medicine Inc., Intellia Therapeutics Inc., Orchard Therapeutics plc, Voyager Therapeutics Inc., REGENXBIO Inc., Abeona Therapeutics Inc., and Krystal Biotech Inc.

Key Developments:

In April 2026, Novartis announced the expansion of its community health programs to over 30 countries by 2030, aiming to bridge gaps in heart disease and cancer care access in low-income and rural areas.

In February 2026, Spark Therapeutics, a Roche subsidiary, presented updated long-term follow-up data for LUXTURNA(R), confirming sustained vision improvement in patients with biallelic RPE65 mutation-associated retinal dystrophy.

In December 2025, Roche announced a strategic collaboration with a biotech partner to leverage AI-driven capsid engineering to improve the tissue-specific delivery of its AAV-based gene therapy pipeline.

Therapy Types Covered:

Gene Augmentation Therapy
Gene Editing Therapy
Gene Silencing Therapy
Gene Regulation Therapy
Oncolytic Gene Therapy
Immunogene Therapy

Vector Types Covered:

Viral Vectors
Non-Viral Vectors

Delivery Methods Covered:

In Vivo Gene Therapy
Ex Vivo Gene Therapy

Route of Administrations Covered:

Intravenous
Intramuscular
Intratumoral
Subretinal
Intrathecal

Therapeutic Areas Covered:

Oncology
Neurology
Hematology
Cardiovascular Diseases
Genetic Disorders
Ophthalmology
Infectious Diseases
Metabolic Disorders
Musculoskeletal Disorders
Other Therapeutic Areas

Gene Types Covered:

Cytokine Genes
Tumor Suppressor Genes
Suicide Genes
Antigen Genes
Deficiency Genes
Other Gene Types

Stage of Developments Covered:

Commercialized Therapies
Late-Stage Pipeline (Phase III)
Mid-Stage Pipeline (Phase II)
Early-Stage Pipeline (Phase I)
Preclinical & Discovery Stage

Applications Covered:

Cancer Treatment
Rare Disease Treatment
Regenerative Medicine
Vaccinology
Personalized Medicine

End Users Covered:

Hospitals & Clinics
Specialty Clinics
Research Institutes
Academic Institutes

Regions Covered:

North America
- United States
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
Rest of the World (RoW)
- Middle East
Saudi Arabia
United Arab Emirates
Qatar
Israel
Rest of Middle East
- Africa
South Africa
Egypt
Morocco
Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations

2 Research Framework

2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
- 2.4.1 Data Collection (Primary and Secondary)
- 2.4.2 Data Modeling and Estimation Techniques
- 2.4.3 Data Validation and Triangulation
- 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

4.1 Porter's Five Forces Analysis
- 4.1.1 Supplier Bargaining Power
- 4.1.2 Buyer Bargaining Power
- 4.1.3 Threat of Substitutes
- 4.1.4 Threat of New Entrants
- 4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison

5 Global Gene Therapy Market, By Therapy Type

5.1 Gene Augmentation Therapy
5.2 Gene Editing Therapy
5.3 Gene Silencing Therapy
5.4 Gene Regulation Therapy
5.5 Oncolytic Gene Therapy
5.6 Immunogene Therapy

6 Global Gene Therapy Market, By Vector Type

6.1 Viral Vectors
- 6.1.1 Adeno-Associated Virus (AAV)
- 6.1.2 Adenovirus
- 6.1.3 Lentivirus
- 6.1.4 Retrovirus
- 6.1.5 Herpes Simplex Virus
- 6.1.6 Other Viral Vectors
6.2 Non-Viral Vectors
- 6.2.1 Lipid-based Vectors
- 6.2.2 Polymer-based Vectors
- 6.2.3 Naked DNA / Plasmid DNA

7 Global Gene Therapy Market, By Delivery Method

7.1 In Vivo Gene Therapy
7.2 Ex Vivo Gene Therapy

8 Global Gene Therapy Market, By Route of Administration

8.1 Intravenous
8.2 Intramuscular
8.3 Intratumoral
8.4 Subretinal
8.5 Intrathecal

9 Global Gene Therapy Market, By Therapeutic Area

9.1 Oncology
9.2 Neurology
9.3 Hematology
9.4 Cardiovascular Diseases
9.5 Genetic Disorders
9.6 Ophthalmology
9.7 Infectious Diseases
9.8 Metabolic Disorders
9.9 Musculoskeletal Disorders
9.10 Other Therapeutic Areas

10 Global Gene Therapy Market, By Gene Type

10.1 Cytokine Genes
10.2 Tumor Suppressor Genes
10.3 Suicide Genes
10.4 Antigen Genes
10.5 Deficiency Genes
10.6 Other Gene Types

11 Global Gene Therapy Market, By Stage of Development

11.1 Commercialized Therapies
11.2 Late-Stage Pipeline (Phase III)
11.3 Mid-Stage Pipeline (Phase II)
11.4 Early-Stage Pipeline (Phase I)
11.5 Preclinical & Discovery Stage

12 Global Gene Therapy Market, By Application

12.1 Cancer Treatment
12.2 Rare Disease Treatment
12.3 Regenerative Medicine
12.4 Vaccinology
12.5 Personalized Medicine

13 Global Gene Therapy Market, By End User

13.1 Hospitals & Clinics
13.2 Specialty Clinics
13.3 Research Institutes
13.4 Academic Institutes

14 Global Gene Therapy Market, By Geography

14.1 North America
- 14.1.1 United States
- 14.1.2 Canada
- 14.1.3 Mexico
14.2 Europe
- 14.2.1 United Kingdom
- 14.2.2 Germany
- 14.2.3 France
- 14.2.4 Italy
- 14.2.5 Spain
- 14.2.6 Netherlands
- 14.2.7 Belgium
- 14.2.8 Sweden
- 14.2.9 Switzerland
- 14.2.10 Poland
- 14.2.11 Rest of Europe
14.3 Asia Pacific
- 14.3.1 China
- 14.3.2 Japan
- 14.3.3 India
- 14.3.4 South Korea
- 14.3.5 Australia
- 14.3.6 Indonesia
- 14.3.7 Thailand
- 14.3.8 Malaysia
- 14.3.9 Singapore
- 14.3.10 Vietnam
- 14.3.11 Rest of Asia Pacific
14.4 South America
- 14.4.1 Brazil
- 14.4.2 Argentina
- 14.4.3 Colombia
- 14.4.4 Chile
- 14.4.5 Peru
- 14.4.6 Rest of South America
14.5 Rest of the World (RoW)
- 14.5.1 Middle East
  - 14.5.1.1 Saudi Arabia
  - 14.5.1.2 United Arab Emirates
  - 14.5.1.3 Qatar
  - 14.5.1.4 Israel
  - 14.5.1.5 Rest of Middle East
- 14.5.2 Africa
  - 14.5.2.1 South Africa
  - 14.5.2.2 Egypt
  - 14.5.2.3 Morocco
  - 14.5.2.4 Rest of Africa

15 Strategic Market Intelligence

15.1 Industry Value Network and Supply Chain Assessment
15.2 White-Space and Opportunity Mapping
15.3 Product Evolution and Market Life Cycle Analysis
15.4 Channel, Distributor, and Go-to-Market Assessment

16 Industry Developments and Strategic Initiatives

16.1 Mergers and Acquisitions
16.2 Partnerships, Alliances, and Joint Ventures
16.3 New Product Launches and Certifications
16.4 Capacity Expansion and Investments
16.5 Other Strategic Initiatives

17 Company Profiles

17.1 Novartis AG
17.2 Roche Holding AG
17.3 Pfizer Inc.
17.4 Johnson & Johnson
17.5 Gilead Sciences Inc.
17.6 Bluebird Bio Inc.
17.7 BioMarin Pharmaceutical Inc.
17.8 Spark Therapeutics Inc.
17.9 Sarepta Therapeutics Inc.
17.10 UniQure NV
17.11 CRISPR Therapeutics AG
17.12 Editas Medicine Inc.
17.13 Intellia Therapeutics Inc.
17.14 Orchard Therapeutics plc
17.15 Voyager Therapeutics Inc.
17.16 REGENXBIO Inc.
17.17 Abeona Therapeutics Inc.
17.18 Krystal Biotech Inc.

簡介目錄圖表

List of Tables

Table 1 Global Gene Therapy Market Outlook, By Region (2023-2034) ($MN)
Table 2 Global Gene Therapy Market Outlook, By Therapy Type (2023-2034) ($MN)
Table 3 Global Gene Therapy Market Outlook, By Gene Augmentation Therapy (2023-2034) ($MN)
Table 4 Global Gene Therapy Market Outlook, By Gene Editing Therapy (2023-2034) ($MN)
Table 5 Global Gene Therapy Market Outlook, By Gene Silencing Therapy (2023-2034) ($MN)
Table 6 Global Gene Therapy Market Outlook, By Gene Regulation Therapy (2023-2034) ($MN)
Table 7 Global Gene Therapy Market Outlook, By Oncolytic Gene Therapy (2023-2034) ($MN)
Table 8 Global Gene Therapy Market Outlook, By Immunogene Therapy (2023-2034) ($MN)
Table 9 Global Gene Therapy Market Outlook, By Vector Type (2023-2034) ($MN)
Table 10 Global Gene Therapy Market Outlook, By Viral Vectors (2023-2034) ($MN)
Table 11 Global Gene Therapy Market Outlook, By Adeno-Associated Virus (AAV) (2023-2034) ($MN)
Table 12 Global Gene Therapy Market Outlook, By Adenovirus (2023-2034) ($MN)
Table 13 Global Gene Therapy Market Outlook, By Lentivirus (2023-2034) ($MN)
Table 14 Global Gene Therapy Market Outlook, By Retrovirus (2023-2034) ($MN)
Table 15 Global Gene Therapy Market Outlook, By Herpes Simplex Virus (2023-2034) ($MN)
Table 16 Global Gene Therapy Market Outlook, By Other Viral Vectors (2023-2034) ($MN)
Table 17 Global Gene Therapy Market Outlook, By Non-Viral Vectors (2023-2034) ($MN)
Table 18 Global Gene Therapy Market Outlook, By Lipid-based Vectors (2023-2034) ($MN)
Table 19 Global Gene Therapy Market Outlook, By Polymer-based Vectors (2023-2034) ($MN)
Table 20 Global Gene Therapy Market Outlook, By Naked DNA / Plasmid DNA (2023-2034) ($MN)
Table 21 Global Gene Therapy Market Outlook, By Delivery Method (2023-2034) ($MN)
Table 22 Global Gene Therapy Market Outlook, By In Vivo Gene Therapy (2023-2034) ($MN)
Table 23 Global Gene Therapy Market Outlook, By Ex Vivo Gene Therapy (2023-2034) ($MN)
Table 24 Global Gene Therapy Market Outlook, By Route of Administration (2023-2034) ($MN)
Table 25 Global Gene Therapy Market Outlook, By Intravenous (2023-2034) ($MN)
Table 26 Global Gene Therapy Market Outlook, By Intramuscular (2023-2034) ($MN)
Table 27 Global Gene Therapy Market Outlook, By Intratumoral (2023-2034) ($MN)
Table 28 Global Gene Therapy Market Outlook, By Subretinal (2023-2034) ($MN)
Table 29 Global Gene Therapy Market Outlook, By Intrathecal (2023-2034) ($MN)
Table 30 Global Gene Therapy Market Outlook, By Therapeutic Area (2023-2034) ($MN)
Table 31 Global Gene Therapy Market Outlook, By Oncology (2023-2034) ($MN)
Table 32 Global Gene Therapy Market Outlook, By Neurology (2023-2034) ($MN)
Table 33 Global Gene Therapy Market Outlook, By Hematology (2023-2034) ($MN)
Table 34 Global Gene Therapy Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
Table 35 Global Gene Therapy Market Outlook, By Genetic Disorders (2023-2034) ($MN)
Table 36 Global Gene Therapy Market Outlook, By Ophthalmology (2023-2034) ($MN)
Table 37 Global Gene Therapy Market Outlook, By Infectious Diseases (2023-2034) ($MN)
Table 38 Global Gene Therapy Market Outlook, By Metabolic Disorders (2023-2034) ($MN)
Table 39 Global Gene Therapy Market Outlook, By Musculoskeletal Disorders (2023-2034) ($MN)
Table 40 Global Gene Therapy Market Outlook, By Other Therapeutic Areas (2023-2034) ($MN)
Table 41 Global Gene Therapy Market Outlook, By Gene Type (2023-2034) ($MN)
Table 42 Global Gene Therapy Market Outlook, By Cytokine Genes (2023-2034) ($MN)
Table 43 Global Gene Therapy Market Outlook, By Tumor Suppressor Genes (2023-2034) ($MN)
Table 44 Global Gene Therapy Market Outlook, By Suicide Genes (2023-2034) ($MN)
Table 45 Global Gene Therapy Market Outlook, By Antigen Genes (2023-2034) ($MN)
Table 46 Global Gene Therapy Market Outlook, By Deficiency Genes (2023-2034) ($MN)
Table 47 Global Gene Therapy Market Outlook, By Other Gene Types (2023-2034) ($MN)
Table 48 Global Gene Therapy Market Outlook, By Stage of Development (2023-2034) ($MN)
Table 49 Global Gene Therapy Market Outlook, By Commercialized Therapies (2023-2034) ($MN)
Table 50 Global Gene Therapy Market Outlook, By Late-Stage Pipeline (Phase III) (2023-2034) ($MN)
Table 51 Global Gene Therapy Market Outlook, By Mid-Stage Pipeline (Phase II) (2023-2034) ($MN)
Table 52 Global Gene Therapy Market Outlook, By Early-Stage Pipeline (Phase I) (2023-2034) ($MN)
Table 53 Global Gene Therapy Market Outlook, By Preclinical & Discovery Stage (2023-2034) ($MN)
Table 54 Global Gene Therapy Market Outlook, By Application (2023-2034) ($MN)
Table 55 Global Gene Therapy Market Outlook, By Cancer Treatment (2023-2034) ($MN)
Table 56 Global Gene Therapy Market Outlook, By Rare Disease Treatment (2023-2034) ($MN)
Table 57 Global Gene Therapy Market Outlook, By Regenerative Medicine (2023-2034) ($MN)
Table 58 Global Gene Therapy Market Outlook, By Vaccinology (2023-2034) ($MN)
Table 59 Global Gene Therapy Market Outlook, By Personalized Medicine (2023-2034) ($MN)
Table 60 Global Gene Therapy Market Outlook, By End User (2023-2034) ($MN)
Table 61 Global Gene Therapy Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
Table 62 Global Gene Therapy Market Outlook, By Specialty Clinics (2023-2034) ($MN)
Table 63 Global Gene Therapy Market Outlook, By Research Institutes (2023-2034) ($MN)
Table 64 Global Gene Therapy Market Outlook, By Academic Institutes (2023-2034) ($MN)